Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice

Vaccine

Volumn 33, Issue 32, 2015, Pages 4035-4040

  Liu, Qiliang ^a,b   Xue, Chunyi ^a   Zheng, Jing ^a   Liu, Kang ^a   Wang, Yang ^a   Wei, Ying ^a   Liu, George Dacai ^c   Cao, Yongchang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUILIN MEDICAL UNIVERSITY   (China)

^c Firstline Biopharmaceuticals Corporation   (United States)

Author keywords

Heterosubtypic protection; Influenza A virus; Multivalent vaccine

Indexed keywords

IMMUNOGLOBULIN G; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT H1 HEMAGGLUTININ; RECOMBINANT H3 HEMAGGLUTININ; UNCLASSIFIED DRUG; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG MEGADOSE; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BODY WEIGHT; CROSS PROTECTION; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOLOGY; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS;

ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; CROSS PROTECTION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA VACCINES; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC;

EID: 84937524486     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.044     Document Type: Article

References (32)

1. Cox N.J., Subbarao K. Influenza. Lancet 1999, 354:1277-1282.
2. Snacken R., Broberg E., Beaute J., Lozano J.E., Zucs P., Amato-Gauci A.J. Influenza season 2012-2013 in Europe: moderate intensity, mixed (sub)types. Epidemiol Infect 2014, 142:1809-1812.
3. Nelson M.I., Holmes E.C. The evolution of epidemic influenza. Nat Rev Genet 2007, 8:196-205.
4. Lee P.S., Ohshima N., Stanfield R.L., Yu W., Iba Y., Okuno Y., et al. Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Nat Commun 2014, 5:3614.
5. Pica N., Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 2013, 64:189-202.
6. Reed C., Meltzer M.I., Finelli L., Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30:1993-1998.
7. Tinoco J.C., Pavia-Ruz N., Cruz-Valdez A., Doniz C.A., Chandrasekaran V., Dewe W., et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. Vaccine 2014, 32:1480-1487.
8. Hess R.D., Weber F., Watson K., Schmitt S. Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine 2012, 30:2715-2727.
9. Tan G.S., Lee P.S., Hoffman R.M., Mazel-Sanchez B., Krammer F., Leon P.E., et al. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza a virus hemagglutinin. J Virol 2014, 88:13580-13592.
10. Lee V.J., Tay J.K., Chen M.I., Phoon M.C., Xie M.L., Wu Y., et al. Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains. Vaccine 2010, 28:6852-6857.
11. Liu Q., Liu K., Xue C., Zhou J., Li X., Luo D., et al. Recombinant influenza H1, H5 and H9 hemagglutinins containing replaced H3 hemagglutinin transmembrane domain showed enhanced heterosubtypic protection in mice. Vaccine 2014, 32:3041-3049.
12. Chen J.X., Xue H.J., Ye W.C., Fang B.H., Liu Y.H., Yuan S.H., et al. Activity of andrographolide and its derivatives against influenza virus in vivo and in vitro. Biol Pharm Bull 2009, 32:1385-1391.
13. Qiao C., Tian G., Jiang Y., Li Y., Shi J., Yu K., et al. Vaccines developed for H5 highly pathogenic avian influenza in China. Ann NY Acad Sci 2006, 1081:182-192.
14. Park P.S., Wells J.W. Monomers and oligomers of the M2 muscarinic cholinergic receptor purified from Sf9 cells. Biochemistry 2003, 42:12960-12971.
15. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23:5751-5759.
16. Miller D.S., Kok T., Li P. The virus inoculum volume influences outcome of influenza A infection in mice. Lab Anim-UK 2013, 47:74-77.
17. Kang S.M., Guo L., Yao Q., Skountzou I., Compans R.W. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J Virol 2004, 78:9624-9632.
18. Quan F.S., Huang C., Compans R.W., Kang S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007, 81:3514-3524.
19. Lin S.C., Huang M.H., Tsou P.C., Huang L.M., Chong P., Wu S.C. Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS ONE 2011, 6:e20052.
20. Lee Y.T., Kim K.H., Ko E.J., Lee Y.N., Kim M.C., Kwon Y.M., et al. New vaccines against influenza virus. Clin Exp Vaccine Res 2014, 3:12-28.
21. Greenberg D.P., Robertson C.A., Noss M.J., Blatter M.M., Biedenbender R., Decker M.D. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013, 31:770-776.
22. Edwards K.M., Decker M.D. Combination vaccines: hopes and challenges. Pediatr Infect Dis J 1994, 13:345-347.
23. Kedl R.M., Kappler J.W., Marrack P. Epitope dominance, competition and T cell affinity maturation. Curr Opin Immunol 2003, 15:120-127.
24. Zinder D., Bedford T., Gupta S., Pascual M. The roles of competition and mutation in shaping antigenic and genetic diversity in influenza. PLoS Pathog 2013, 9:e1003104.
25. Pross H.F., Eidinger D. Antigenic competition: a review of nonspecific antigen-induced suppression. Adv Immunol 1974, 18:133-168.
26. Taussig M.J. Antigenic competition. Curr Top Microbiol Immunol 1973, 60:125-174.
27. Pobre K., Tashani M., Ridda I., Rashid H., Wong M., Booy R. Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines. Vaccine 2014, 32:1423-1430.
28. Hunt J.D., Jackson D.C., Brown L.E., Wood P.R., Stewart D.J. Antigenic competition in a multivalent foot rot vaccine. Vaccine 1994, 12:457-464.
29. Keitel W.A., Treanor J.J., El Sahly H.M., Gilbert A., Meyer A.L., Patriarca P.A., et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine 2009, 28:379-385.
30. Van der Vliet D., Pepin S., Lambert M., Fauchoux N., Donazzolo Y., Dupuy M., et al. Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine. Hum Vaccines 2010, 6:823-828.
31. Steel J., Lowen A.C., Wang T.T., Yondola M., Gao Q., Haye K., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010, 1. 00018-10.
32. Stanekova Z., Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J 2010, 7:351.